Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 3/20 | 0.34 |
| ▸ | ATR | Q13535 | 5/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17255824 | 0.84 | PIK3CD (0.88) | PIK3CDPIK3CAPIK3CBPIK3CGPRKCQ | |
| SCHEMBL111185 | 0.84 | PIK3CD (0.45) | PIK3CDPIK3CAPIK3CBPIK3CGHTR6 | |
| Hydrochloric Acid SCHEMBL17255819 | 0.83 | PIK3CD (0.87) | PIK3CDPIK3CAPIK3CBPIK3CGPRKCQ | |
| SCHEMBL15051784 | 0.83 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGPRKCQ | |
| SCHEMBL20212531 | 0.83 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPRKCQ | |
| Nemiralisib SCHEMBL29356978 | 0.80 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKCQ | |
| Nemiralisib SCHEMBL29493085 | 0.80 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKCQ | |
| Nemiralisib SCHEMBL109919 | 0.80 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKCQ | |
| Nemiralisib SCHEMBL659144 | 0.80 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGPRKCQ | |
| Nemiralisib SCHEMBL111259 | 0.80 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632921-B1 | POLYMORPHS AND SALTS OF 6-(1H-INDOL-4-YL)-4-(5-{[4-(1-METHYLETHYL)-1-PIPERAZINYL]METHYL}-1,3-OXAZOL-2-YL)-1H-INDAZOLE AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF E.G. RESPIRATORY DISORDERS | GLAXO GROUP LTD (GB) | 2018-10-17 | — | — | EP | disclosed |
| EP-2613781-B1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-08-24 | — | — | EP | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-8993576-B2 | 6-(1H-indol-4-yl)-4-(5-{[4-1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hemi succinate salt, polymorphs and pharmaceutical compositions thereof | GLAXO GROUP LIMITED (GB) | 2015-03-31 | — | — | US | disclosed |
| US-8993576-B2 | 6-(1H-indol-4-yl)-4-(5-{[4-1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hemi succinate salt, polymorphs and pharmaceutical compositions thereof | GLAXO GROUP LIMITED (GB) | 2015-03-31 | — | — | US | disclosed |
| US-8993576-B2 | 6-(1H-indol-4-yl)-4-(5-{[4-1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hemi succinate salt, polymorphs and pharmaceutical compositions thereof | GLAXO GROUP LIMITED (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2632921-A1 | POLYMORPHS AND SALTS OF 6-(1H-INDOL-4-YL)-4-(5- { [4-(1-METHYLETHYL)-1-PI PERAZINYL]METHYL} -1,3-OXAZOL-2-YL)-1H-INDAZOLE AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF E.G. RESPIRATORY DISORDERS | Glaxo Group Limited (GB) | 2013-09-04 | — | — | EP | disclosed |
| CN-103270037-A | Polymorphs and salts of 6-1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)- 1-pi perazinyl] methyl} -1,3-oxazol-2-group)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders | GLAXO GROUP LTD | 2013-08-28 | — | — | CN | disclosed |
| US-20130203772-A1 | Polymorphs and Salts | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130203772-A1 | Polymorphs and Salts | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130203772-A1 | Polymorphs and Salts | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012055846-A1 | POLYMORPHS AND SALTS OF 6-(1H-INDOL-4-YL)-4-(5- { [4-(1-METHYLETHYL)-1-PI PERAZINYL] METHYL} -1,3-OXAZOL-2-YL)-1H-INDAZOLE AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF E.G. RESPIRATORY DISORDERS | GLAXO GROUP LIMITED (GB) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055846-A1 | POLYMORPHS AND SALTS OF 6-(1H-INDOL-4-YL)-4-(5- { [4-(1-METHYLETHYL)-1-PI PERAZINYL] METHYL} -1,3-OXAZOL-2-YL)-1H-INDAZOLE AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF E.G. RESPIRATORY DISORDERS | GLAXO GROUP LIMITED (GB) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203772-A1 | Polymorphs and Salts | PRKDC, PRKACA, MAP3K6 | PIK3CD 211/4885PIK3CA 117/4885PIK3CB 279/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CA 2691/4885PIK3CB 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.